Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Pruritus, commonly referred to as chronic kidney disease–associated pruritus (CKD-aP), is a distressing and under-recognized symptom among patients with advanced CKD. CKD-aP remains a significant healthcare concern due to its negative impact on patient-reported outcomes, including reduced quality of life, impaired sleep, depression, and anxiety. However, most studies to date have focused on patients receiving haemodialysis. The primary aim of this study was to determine the prevalence of CKD-aP in patients undergoing peritoneal dialysis (PD) and to examine its association with patient-reported outcomes.
A cross-sectional study was conducted among patients aged ≥18 years undergoing PD within Western Sydney. CKD-aP and its severity were assessed using the 5-D Itch Scale and the Worst Itch Numerical Rating Scale (WI-NRS), respectively. Symptom burden was evaluated using the IPOS-Renal Scale, while health-related quality of life (HRQoL) was measured with the SF-36 questionnaire. Depression and anxiety were assessed using the Patient Health Questionnaire-9 (PHQ-9) and Beck Anxiety Inventory. Statistical analyses were performed using IBM SPSS Statistics (Version 24), with p < 0.05 considered statistically significant.
A total of 160 PD patients were included, with a mean (SD) age of 62 (16) years, and 52% (n = 84) were male. Ninety-one patients (59.1%) were on automated PD. CKD-aP was reported by 114 patients (71%), of whom 84 (74%) experienced moderate to severe itch. Higher serum phosphate levels were significantly associated with CKD-aP (p = 0.006), and patients with moderate to severe CKD-aP reported poorer quality of life (p = 0.002).
CKD-aP was present in more than two-thirds of PD patients, with most experiencing moderate to severe itch. The condition was significantly associated with higher serum phosphate levels and poorer quality of life. Future research should focus on identifying modifiable risk factors and developing targeted management strategies to alleviate symptom burden in CKD-aP.
